Asunto(s)
Lepra/inmunología , Formación de Roseta , Linfocitos T/inmunología , Adolescente , Adulto , Anciano , Femenino , Humanos , Inmunidad Celular , Recuento de Leucocitos , Masculino , Persona de Mediana EdadAsunto(s)
Levamisol/efectos adversos , Adolescente , Adulto , Anciano , Niño , Femenino , Humanos , Lepra/tratamiento farmacológico , Levamisol/uso terapéutico , Masculino , Persona de Mediana EdadRESUMEN
A 150 mg levamisole tablet once in every fortnight along with specific antileprosy drugs were administered to ten patients each in BL and LL groups of leprosy. A similar number of patients in each group receiving only specific antileprosy treatment served as controls. After 11/2 years of study a more significant improvement was noted in the bacteriological status in the levamisole-treated group. Thus, levamisole can be used as an effective adjunct for quicker recovery in lepromatous patients.
Asunto(s)
Lepra/tratamiento farmacológico , Levamisol/uso terapéutico , Adulto , Dapsona/uso terapéutico , Femenino , Humanos , MasculinoRESUMEN
Levamisole, the anthelmintic drug was tried in ENL (Erythema Nodosum Leprosum) cases using double blind control trial in dosage of 150 mg/day on three consecutive days for three months. It was found that levamisole was not effective in ENL cases and no severe side effect was seen in these cases.
Asunto(s)
Eritema Nudoso/tratamiento farmacológico , Lepra/tratamiento farmacológico , Levamisol/uso terapéutico , Adolescente , Adulto , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Ninety adult leprosy patients attending the skin outpatient department of Institute Hospital of Varanasi, India, were selected for the study. A group of thirty patients including 10 cases of lepromatous, 10 of borderline and 10 cases in reaction of which 5 were of type 1 and 5 of type II reaction were treated with levamisole and DDS. Levamisole was given in the doses of 150 mg. daily for three consecutive days which was repeated after every 12 days. The effects were compared with two similar groups receiving clofazimine plus DDS and DDS alone respectively for six months. It was observed that levamisole was useful in bringing down both the types of reactions in a period shorter than required by clofazimine. Clinical improvement in non-reaction cases was found to be similar in all the three groups. Minor side effects were also seen with levamisole and clofazimine in some cases.
Asunto(s)
Lepra/tratamiento farmacológico , Levamisol/uso terapéutico , Clofazimina/uso terapéutico , Dapsona/uso terapéutico , Quimioterapia Combinada , Eritema Nudoso/tratamiento farmacológico , Humanos , Lepra/inmunología , Levamisol/efectos adversos , RecurrenciaRESUMEN
Eleven cases of borderline-borderline leprosy were subjected to levamisole therapy for 3 months. Levamisole was given 150 mg/day on three consecutive days every fortnight along with dapsone (DDS). Immuno-stimulation was assessed by lepromin test using Lepromin-A supplied by W.H.O. containing 4.0 X 10(7) bacilli per milli litre. It was found that there was statistically significant change in lepromin reaction after levamisole therapy.